Indokem

Why is Indokem Ltd falling/rising?

As of 22-Jun, Indokem Ltd's stock price is at 499.75, down 0.25 (-0.05%). Despite recent declines and a bearish trend, there are short-term recovery signs, including outperformance against its sector and increased investor participation.

As of 22-Jun, Indokem Ltd's stock price is currently at 499.75, reflecting a slight decline of 0.25 (-0.05%). The stock has experienced a negative performance over various periods, including a 1-week decline of 2.10% and a significant 1-month drop of 15.99%. Year-to-date, the stock is down 20.23%, although it has shown remarkable growth over the past year with an increase of 114.30%.<BR><BR>Despite the current decline, there are some positive indicators. The stock has outperformed its sector by 0.65% today and has gained 1.81% over the last two days. Additionally, there has been a rise in investor participation, with delivery volume increasing by 14.08% compared to the 5-day average. However, the stock is trading below its moving averages across multiple time frames, indicating a bearish trend.<BR><BR>Overall, while there are some signs of recovery in the short term, the longer-term performance and current trading conditions suggest that Indokem Ltd is facing downward pressure on its stock price.

Which are the latest news on Indokem?

How big is Indokem?

As of 10th June, Indokem Ltd has a market capitalization of 1,425.00 Cr, classifying it as a Micro Cap company, with recent net sales of 169.39 Cr and a net profit of 1.87 Cr. Shareholder's Funds and Total Assets values are not available.

As of 10th June, Indokem Ltd has a market capitalization of 1,425.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, Indokem reported net sales of 169.39 Cr and a net profit of 1.87 Cr.<BR><BR>The reporting period for the balance sheet is the latest annual period. However, the values for Shareholder's Funds and Total Assets are not available.

Who are in the management team of Indokem?

The management team of Indokem includes Mahendra K Khatau (Chairman/Executive Director), Manish M Khatau (Whole-Time Director), Asha M Khatau (Non-Executive Director), and several independent directors, ensuring a blend of executive leadership and independent oversight.

The management team of Indokem includes the following individuals:<BR><BR>1. **Mahendra K Khatau** - Chairman / Executive Director<BR>2. **Manish M Khatau** - Whole-Time Director & Executive Director<BR>3. **Asha M Khatau** - Non-Executive Director<BR>4. **Kailash Pershad** - Independent Non-Executive Director<BR>5. **Bhalchandra Sontakke** - Independent Non-Executive Director<BR>6. **Rahul Singh** - Independent Non-Executive Director<BR>7. **Sneha Vidyadhar Khandekar** - Independent Director<BR>8. **Suyash Neelkanth Bhise** - Independent Director<BR>9. **Adarsh Pankaj Shukla** - Independent Director<BR>10. **Arup Basu** - Non-Executive Director<BR><BR>This team brings a mix of executive and independent oversight to the company.

Who are the peers of the Indokem?

Indokem's peers include Camlin Fine, Bhansali Engg., Titan Biotech, S H Kelkar & Co., Vidhi Specialty, Nitta Gelatin, Platinum Industr, Excel Industries, and Paushak. Indokem has average management risk and growth, with a 1-year return of 121.35%, lower than Titan Biotech's 412.73% but higher than Camlin Fine's -57.63%.

Peers: The peers of Indokem are Camlin Fine, Bhansali Engg., Titan Biotech, S H Kelkar & Co., Vidhi Specialty, Nitta Gelatin, Platinum Industr, Excel Industries, and Paushak.<BR><BR>Quality Snapshot: Excellent management risk is observed at Bhansali Engg., Titan Biotech, Nitta Gelatin, Platinum Industr, Excel Industries, Paushak, and the rest. Average management risk is found at S H Kelkar & Co., Vidhi Specialty, and the rest. Below Average management risk is noted for Camlin Fine and Indokem. In terms of growth, Excellent growth is seen at Nitta Gelatin, Platinum Industr, Excel Industries, and Paushak, while Average growth is observed at Indokem and the rest. Below Average growth is present at Camlin Fine, Bhansali Engg., Titan Biotech, S H Kelkar & Co., Vidhi Specialty, and the rest. For Capital Structure, Excellent capital structure is noted at Bhansali Engg., Titan Biotech, Vidhi Specialty, Nitta Gelatin, Platinum Industr, Excel Industries, Paushak, and the rest, while Average capital structure is found at S H Kelkar & Co. and Indokem, and Below Average capital structure is seen at Camlin Fine.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Titan Biotech at 412.73%, while the peer with the lowest 1-year return is Camlin Fine at -57.63%. Indokem's own 1-year return is 121.35%, which is significantly higher than Camlin Fine's but lower than Titan Biotech's. Additionally, the six-month return is negative for Camlin Fine, S H Kelkar & Co., Vidhi Specialty, Platinum Industr, Excel Industries, and Paushak.

What does Indokem do?

Indokem Ltd is a micro-cap company in the specialty chemicals industry, primarily producing dyes and chemicals for textiles, with a market cap of INR 1,425 Cr. As of March 2026, it reported net sales of 46 Cr and a net profit of 0 Cr.

Overview: <BR>Indokem Ltd is a micro-cap company operating in the specialty chemicals industry, primarily manufacturing dyes, sizing chemicals, and auxiliaries for the textile sector, as well as dealing in electrical capacitors.<BR><BR>History: <BR>Indokem Ltd, formerly known as Khatau Junker Limited, is part of the Khatau Mahendra Group and was promoted by Dharamsey Khatau. The latest quarterly results reported net sales and net profit for the period ending March 2026.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 46 Cr (Quarterly Results - Mar 2026) <BR>Most recent Net Profit: 0 Cr (Quarterly Results - Mar 2026) <BR>Market-cap value: INR 1,425 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: 753.00 <BR>Industry P/E: 20 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 0.35 <BR>Return on Equity: 2.90% <BR>Price to Book: 21.83 <BR><BR>Contact Details: <BR>Address: Khatau House Plot No 410/411, 1st Flr Mogul Lane Mahim (Wes Mumbai Maharashtra : 400016 <BR>Tel: 91-22-61236767/61236711 <BR>Email: iklsecretarial@gmail.com <BR>Website: http://www.indokem.co.in

Are Indokem Ltd latest results good or bad?

Indokem Ltd's latest results are concerning, showing a 90.81% decline in net profit and a 16.41% drop in revenue year-on-year, alongside a significant decrease in operating margin. These trends suggest that the company's recent stock performance may not be sustainable.

Indokem Ltd's latest results indicate a concerning trend for the company. In the fourth quarter of FY26, the company reported a net profit of ₹0.35 crore, which represents a staggering decline of 90.81% year-on-year. Additionally, revenue fell by 16.41% to ₹45.50 crore compared to the same quarter last year. <BR><BR>The operating margin also suffered significantly, dropping from 9.57% in the previous year to just 3.54%. This sharp decline in profitability raises questions about the sustainability of the company's recent stock performance, which has seen a remarkable increase of 345.09% over the past year. <BR><BR>While the stock has performed well in the past, the latest results highlight severe operational challenges and a collapse in profitability, suggesting that the recent rally may not be supported by underlying fundamentals. Overall, the latest results can be interpreted as bad, given the dramatic profit decline and margin compression.

Should I buy, sell or hold Indokem Ltd?

When is the next results date for Indokem Ltd?

The next results date for Indokem Ltd is 04 May 2026.

The next results date for Indokem Ltd is scheduled for 04 May 2026.

How has been the historical performance of Indokem?

Indokem's financial performance has significantly improved over the past three years, with net sales reaching 178.09 crore in March 2025, a turnaround to positive profits, and an earnings per share increase to 1.14, reflecting enhanced profitability and operational efficiency.

Answer:<BR>Indokem has shown a notable improvement in its financial performance over the past three years, particularly in the fiscal year ending March 2025. The company's net sales increased to 178.09 crore in March 2025 from 164.80 crore in March 2024 and 111.86 crore in March 2023. Total operating income mirrored this growth, reaching 178.09 crore in March 2025. Despite rising raw material costs, which were 119.63 crore in March 2025 compared to 109.53 crore in March 2024 and 77.39 crore in March 2023, the company managed to achieve an operating profit (PBDIT) of 8.37 crore in March 2025, a significant recovery from a loss of 0.60 crore in March 2024. The profit before tax also turned positive at 3.29 crore in March 2025, compared to a loss of 6.19 crore in the previous year. Consequently, profit after tax rose to 3.14 crore in March 2025, a stark contrast to the loss of 6.23 crore in March 2024. The earnings per share (EPS) improved to 1.14 in March 2025 from a negative 2.22 in March 2024. The company's cash flow from operating activities also increased to 5.00 crore in March 2025, up from 4.00 crore in March 2024 and 2.00 crore in March 2023, resulting in a closing cash and cash equivalent of 3.00 crore in March 2025.<BR><BR>Breakdown:<BR>Indokem's financial trajectory has been marked by significant growth in net sales, which rose to 178.09 crore in March 2025, reflecting a robust recovery from the previous years. The total operating income followed suit, indicating effective management despite escalating raw material costs. The operating profit turned positive, showcasing a turnaround from losses in prior years, while profit before tax and profit after tax both returned to positive figures, highlighting improved profitability. The earnings per share also saw a remarkable recovery, indicating enhanced shareholder value. Furthermore, the cash flow from operating activities demonstrated consistent growth, culminating in a healthy closing cash position, which suggests improved liquidity and operational efficiency.

Is Indokem overvalued or undervalued?

As of June 26, 2025, Indokem is considered very expensive with a PE ratio of 225.97, significantly higher than its peers, indicating overvaluation despite a 172.17% return over the past year.

As of 26 June 2025, the valuation grade for Indokem has moved from expensive to very expensive, indicating a significant increase in perceived overvaluation. The company is currently assessed as overvalued, with a PE ratio of 225.97, an EV to EBITDA of 96.21, and a Price to Book Value of 11.59. These ratios suggest that the stock is trading at a premium compared to its earnings and book value, which raises concerns about its sustainability at these levels.<BR><BR>When compared to peers, Indokem's valuation stands out starkly; for instance, Sudarshan Chemicals, which is categorized as expensive, has a PE ratio of 73.54, while Kiri Industries, deemed risky, has a PE ratio of just 13. Additionally, Vidhi Specialty, also classified as very expensive, has a PE ratio of 47.93. The substantial disparity in these ratios reinforces the notion that Indokem is overvalued. Notably, the company's stock has outperformed the Sensex significantly over the past year, with a return of 172.17% compared to the Sensex's 6.46%, which may have contributed to the inflated valuation.

Is Indokem technically bullish or bearish?

As of June 10, 2025, the technical trend is bullish, supported by strong indicators like the MACD and Bollinger Bands, despite a mildly bearish KST signal on the weekly timeframe.

As of 10 June 2025, the technical trend has changed from mildly bullish to bullish. The current stance is bullish with strong indicators supporting this position. The MACD is bullish on both the weekly and monthly time frames, and Bollinger Bands also indicate bullishness in both time frames. Daily moving averages confirm a bullish trend. Although the KST shows a mildly bearish signal on the weekly, the overall monthly outlook remains bullish. Dow Theory supports this bullish sentiment across both weekly and monthly analyses. The stock has shown significant returns compared to the Sensex, further reinforcing the bullish stance.

Who are the top shareholders of the Indokem?

The top shareholder of Indokem is Vindhyapriya Holdings Pvt Ltd, with a 19.76% stake. Promoters hold the majority of shares, while individual investors own 26.51%, and the highest public shareholder is Sangeetha S at 1.8%.

The top shareholders of Indokem include Vindhyapriya Holdings Pvt Ltd, which holds the largest share at 19.76%. The majority of the company's shares are held by promoters, with no pledged promoter holdings reported. Additionally, individual investors collectively hold 26.51% of the shares. The highest public shareholder is Sangeetha S, with a holding of 1.8%. There are also 10 mutual fund schemes that hold a small portion of the shares, amounting to 0.1%, but there are no foreign institutional investors involved.

Has Indokem declared dividend?

No Dividend History Available